Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula

Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers

RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers th

Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre

On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results

Evommune halts EVO756 development in atopic dermatitis following a Phase 2b trial failure, shifting

Mission Produce rose 5.5% after beating Q3 earnings and sales estimates; several stocks rallied, whi

Evommune said on Tuesday it will not advance its experimental skin disease drug ​after it failed to

Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) s

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommu

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Con

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market

Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and a

Evommune, Inc. (NYSE: EVMN - Get Free Report) has been given a consensus recommendation of "Moderate

RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers th

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa

PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evomm

Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chroni

Oversold health care stocks: EVMN, NNNN, NAUT. RSI <30 shows they may be undervalued. EVMN drop

Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this cre

Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier

Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the compan

Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers

Wall Street analysts changed outlook on top names, including Alphine Income Property Trust, AAR Corp

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday

Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 poi

Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechn

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommu

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) with a Buy and

Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and raises

Evommune (NYSE:EVMN) reported quarterly losses of $(0.64) per share which beat the analyst consensus

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa

 Up to 4,494,279 Shares of Common StockThis prospectus relates to the resale from time to time of up

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist i

RBC Capital analyst Brian Abrahams reiterates Evommune (NYSE:EVMN) with a Outperform and maintain

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa

Capricorn Fund Managers Ltd acquired a new stake in Evommune, Inc. (NYSE: EVMN) in the fourth quarte

Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright &

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and

Clear Street analyst Kaveri Pohlman initiates coverage on Evommune (NYSE:EVMN) with a Buy rating

Shares of Evommune, Inc. (NYSE: EVMN - Get Free Report) have been assigned an average rating of "Mod

Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than

Evommune (NYSE:EVMN) reported quarterly losses of $(1.43) per share which missed the analyst consens

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa

The Benzinga Stock Whisper Index highlights five stocks seeing strong interest from readers during t

Evommune, Inc. (NYSE: EVMN - Get Free Report) has earned a consensus rating of "Moderate Buy" from t